Aerosolized amikacin for treatment of pulmonary Mycobacterium aviuminfections: an observational case series
Current systemic therapy for nontuberculous mycobacterial pulmonary infection is limited by poor clinical response rates, drug toxicities and side effects. The addition of aerosolized amikacin to standard oral...